Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Eli Lilly

Viking Therapeutics

Novo Nordisk's popular weight loss drug significantly reduced the risk of heart attack or stroke in a late-stage trial. These data bode well for the obesity drug category at large.

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Are On Fire Today

Shares of Novo Nordisk A/S (NYSE: NVO) are up 17% this morning after the pharmaceutical behemoth reported results of its “SELECT” trial.

Novo Nordisk shares jump another 17% on the back of obesity drug

New data show Novo Nordisk's Wegovy reduces risk of heart attack and stroke, paving the way for greater insurance coverage.

The Obesity Drug Revolution Just Got Real

Novo Nordisk stock surged Tuesday after the firm said its weight-loss drug reduced the risk of cardiovascular events.

Novo Nordisk, Eli Lilly Break Out As New Evidence Bolsters Weight-Loss Drugs

Novo Nordisk (NYSE:NVO) shares soared as the Danish pharma reported its new treatment Wegovy reduced heart problems well as weight in on ongoing trial. Obesity treatment semaglutide (marketed as Wegovy) met its primary endpoint by reducing cardiovascular events by 20% in adults with overweight or obesity compared with placebo in the trial called Select.

Novo Nordisk weight loss drug impresses in heart trial

Novo Nordisk's anti-obesity drug reduced people's risk of suffering heart attacks, strokes and cardiovascular deaths by 20%.

Weight-Loss Drug Wegovy Cuts Heart Attack, Stroke Risk by 20% in New Study

The success of Novo Nordisk's NVO, +3.04% NOVO.B, +13.49% Wegovy in reducing cardiovascular events in obese adults is an important win for the obesity category with positive implications for that company and rival Eli Lilly & Co. LLY, +1.02%, Wolfe Research said Tuesday. “The study aimed to show that losing weight (using Wegovy, in this case) would lower things like heart attacks, and the primary endpoint (a reduction in major adverse cardiovascular events, or MACE) was achieved.

Wegovy's success in reducing cardio risk is ‘an important win,' and a ‘best-case scenario,' say Wolfe analysts

Novo Nordisk's U.S.-listed stock NVO, +3.04% NOVO.B, +10.32% rose 10% premarket Tuesday, after the company said its obesity treatment semaglutide, marketed as Wegovy, met its main goal in a trial evaluating its ability to reduce cardiovascular events and not just help with weight loss. The Danish company said a 2.4 mg dose of semaglutide reduced the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the trial called Select compared with placebo.

Novo Nordisk says Wegovy reduced risk of adverse cardiovascular events by 20% in adults with obesity in trial

Bagsværd, Denmark , 8 August 2023 – Novo Nordisk today announced the headline results from the SELECT cardiovascular outcomes trial. The double-blinded trial compared subcutaneous once-weekly semaglutide 2.4 mg with placebo as an adjunct to standard of care for prevention of major adverse cardiovascular events (MACEs) over a period of up to five years. The trial enrolled 17,604 adults aged 45 years or older with overweight or obesity and established cardiovascular disease (CVD) with no prior history of diabetes.

Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial

Novo Nordisk A/S ( NVO , Financial), a leading player in the biotechnology industry, is currently trading at $161.48 with a market capitalization of $361.61 billion. The company's stock price has seen a gain of 3.12% today and an overall increase of 2.77% over the past four weeks.

Novo Nordisk A/S: A Biotech Giant with High Outperformance Potential

Novo Nordisk's valuation is fairly high thanks to its newest weight-loss medicines. Given that it has other medications on the way, its valuation could hold up.

Novo Nordisk Stock Isn't a Bargain. Here's Why You Should Buy It Anyway.

A recent survey found that doctors are most excited about semaglutide in treating NASH. Treating the liver disease could be a massive market over the next few years.

Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy?

ASML Hld

Visa

Companies that pay dividends are often well-established, as they generally are no longer experiencing supercharged growth and opt to share profits with shareholders.

Buy These 3 Top-Ranked Stocks for Dividend Growth

The Ozempic developer detailed its recent share buybacks. It launched a repurchase program at the end of January.

Why Novo Nordisk Stock Thrashed the Market on Monday

Novo Nordisk has launched blockbuster weight-loss drug Wegovy in Germany, its first big European market, hoping Germans will pay hundreds of euros out of pocket for a drug that public health insurance plans are so far barred from covering.

Novo Nordisk weight-loss drug Wegovy launched in Germany, first big EU market

Amylyx Pharmaceuticals

Annovis Bio

Clinical trials can be like a tightrope over a minefield for biotech investors. Only a fraction of drugs even succeed through clinical trials to receive FDA approval.

3 Biotech Stocks to Buy Before Drug Trials End

Ecolab

Hormel Foods

Traders are usually looking for the next big thing and with good reason. Catching new trends, like AI stocks, can lead to strong near-term gains.

3 Long-Term Stocks You Better Be Buying on Each and Every Dip

Apple

Broadcom

Cigna

Cummins

General Dynamics

Lockheed Martin

Lam Research

LyondellBasell Industries

Medical Properties Trust

National Retail Properties

Pfizer

Stanley Black & Decker

AT&T

T. Rowe Price Group

Taiwan Semiconductor Manufacturing

Tyson Foods

Texas Instruments

Union Pacific

I'm your main street neighbor investor in his mid-30s sharing his brokerage account investment journey pursuing a dividend growth strategy. Dividends received YTD totaling $4155 up 18% compared to the same period last year. I believe the current market is strained but I keep investing as often as I can to ensure time in the market as opposed to timing the market.

My International Portfolio: Approaching Another Major Milestone And Looking Into Recent Additions

The UK is reviewing diabetes medicine and weight-loss treatments Ozempic and Saxenda after some patients reported suicidal or self-harming thoughts.

Weight loss and diabetes drugs investigated over suicidal thoughts

Eli Lilly has a couple of promising weight-loss treatments that could gain approval in the near future. Novo Nordisk's obesity care revenue doubled in the first quarter -- and stands to go still higher.

Eli Lilly vs. Novo Nordisk: What's the Better Weight-Loss Stock to Buy?

Genmab - ADR

Vertex Pharmaceuticals

Biotechnology is one of the most exciting and innovative sectors in the market, offering investors the potential for high returns coupled with groundbreaking discoveries. However, due to regulatory hurdles, clinical failures and intense competition, biotech investing also comes with high risks.

3 Biotech Stocks You Better Be Buying on Each and Every Dip

Catalent

The factory that fills the self-injection pens for booming weight-loss drug Wegovy has repeatedly breached U.S. sterile-safety rules in recent years and staff have failed to perform required quality checks, a Reuters review of regulatory documents shows.

Insight: Wegovy weight-loss injection factory plagued by sterile-safety failures

Advanced Micro Devices

Coca-Cola

Microsoft

NVIDIA

UnitedHealth Group

Some of the best-performing stocks, including market monsters helped buoy a rebound in equities. These firms are among the largest corporations in their respective niches and exert significant influence.

7 ‘Monster' Stocks to Buy Right Now

Novo Nordisk's obesity care product, Wegovy®, is experiencing high growth rates since its launch in the US, Denmark, and Norway. We expect to see a sales growth rate of 25% for 2023 and 15% for 2024. Applying a DCF valuation, our fair price is $186, so we are bullish and consider the stock undervalued.

Novo Nordisk: Market Leader In A Growing Market

Britain is reviewing a class of drugs used in a diabetes medicine and a weight-loss treatment sold by Novo Nordisk after some patients reported suicidal or self-harming thoughts, two weeks after similar action by the European Union.

Exclusive: UK probing Novo's Ozempic, weight-loss drug Saxenda over suicidal, self-harming thoughts

News for Novo Nordisk Stock (NVO)